Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update |
| |
Authors: | Giorgia Battipaglia Radwan Massoud Syed Osman Ahmed Ollivier Legrand Jean El Cheikh Riad Youniss Mahmoud Aljurf Mohamad Mohty Ali Bazarbachi |
| |
Institution: | 1. Service d’Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France;2. Department of Hematology and Marrow Transplantation, University Federico II of Naples, Naples, Italy;3. Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon;4. King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia;5. Université Pierre and Marie Curie, Paris, France;6. INSERM, UMRs 938, Paris, France;7. Department of Cell Biology, Anatomy and Physiological Sciences, American University of Beirut, Beirut, Lebanon |
| |
Abstract: | BackgroundPatients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage treatments.Patients and MethodsWe previously reported the safety and efficacy of sorafenib, an FLT3 inhibitor, as a maintenance agent after allo-HSCT in patients diagnosed with AML with FLT3 mutations. We provide an update on the 27 patients with FLT3-mutated AML in our original report, who received sorafenib as a single maintenance agent.ResultsSince our previous report, others have confirmed our reported significant overall survival and progression-free survival in patients who received sorafenib before and/or after allo-HSCT. In this update on the 27 patients with FLT3-mutated AML in our original report, we show persistence of the previously reported impressive long-term disease control.ConclusionOur results, with longer follow-up than in our previous report, together with those of others, further support the use of sorafenib as a maintenance agent after allo-HSCT. |
| |
Keywords: | Address for correspondence: Giorgia Battipaglia MD Hôpital Saint Antoine 184 Rue du Faubourg Saint Antoine 75012 Paris France Allogeneic stem cell transplantation FLT3 mutated acute myeloid leukemia Maintenance treatment Sorafenib Update |
本文献已被 ScienceDirect 等数据库收录! |
|